Skip to content

cGMP: Metabolism and Appetite Modulation

Metabolic Effects of cGMP: From Amino Acid Absorption Kinetics to Appetite Modulation

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06794515
Enrollment
15
Registered
2025-01-27
Start date
2025-02-03
Completion date
2025-04-24
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria. Therefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control. The main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.

Interventions

DIETARY_SUPPLEMENTcGMP-AAs alone (20 g of protein equivalent)

cGMP-AAs alone (20 g of protein equivalent)

DIETARY_SUPPLEMENTcGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple

cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple

DIETARY_SUPPLEMENTcGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil

cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil

Sponsors

Universidade Nova de Lisboa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men or women * Adults (age ≥ 18 years) * Body Mass Index (BMI) between 18.5-25.0 kg/m2 * Filling informed consent

Exclusion criteria

* Clinically significant illness * Have changed frequency, duration, or intensity of physical activity in the last month * Taking protein supplements * Pregnant or breastfeeding * Smoking and drug use

Design outcomes

Primary

MeasureTime frameDescription
Changes in the iAUC (pmol/L*min) for Gastric inhibitory polypeptide (GIP)180 minutesGIP will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for GIP will be calculated based on the concentration curve following consumption of the test meal.
Changes in the iAUC (pmol/L*min) for glucagon-like peptide-1 (GLP-1)180 minutesGLP-1 will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for GLP-1 will be calculated based on the concentration curve following consumption of the test meal.
Changes in the iAUC (pmol/L*min) for Cholecystokinin (CCK)180 minutesCCK will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for CCK will be calculated based on the concentration curve following consumption of the test meal.
Changes in the iAUC (pmol/L*min) for peptide YY (PYY)180 minutesPYY will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (pmol/L\*min) for PYY will be calculated based on the concentration curve following consumption of the test meal.
Changes in the iAUC (mmol/L*min) for total amino acids180 minutesTotal amino acids will be measured in fasting and every 30 minutes up to 180 minutes. The iAUC (mmol/L\*min) for amino acids will be calculated based on the concentration curve following consumption of the test meal.

Secondary

MeasureTime frameDescription
Changes in insulin180 minutesInsulin will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for insulin will be calculated based on the concentration curve following consumption of the test meal.
Changes in C-peptide180 minutesC-peptide will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for C-peptide will be calculated based on the concentration curve following consumption of the test meal.
Changes in glucose180 minutesGlucose will be measured in fasting and every 30 minutes up to 3 hours. The iAUC (mmol/L\*min) for glucose will be calculated based on the concentration curve following consumption of the test meal.

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026